Kaewpoowat Quanhathai, Ostrosky-Zeichner Luis
University of Texas Health Science Center at Houston, Division of Infectious Diseases , 6431 Fannin Street, MSB 2.112, Houston, TX 77030 , USA +1 713 500 6733 ; +1 713 500 5495 ;
Expert Opin Drug Saf. 2015 Feb;14(2):335-42. doi: 10.1517/14740338.2015.997206. Epub 2014 Dec 25.
The emergence of multidrug-resistant (MDR) infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline , a broad spectrum antibiotic covering against many MDR organisms, has been widely used. However, recent meta-analysis studies have raised a concern for its efficacy and safety. Reviewing tigecycline safety data would enhance the appropriate use of this medication.
This article reviews the safety profile of tigecycline, including its side effects and drug interactions.
The increased mortality associated with tigecycline is not yet well understood. Based on current evidence, alternative options must be prioritized over tigecycline if available. When tigecycline use is warranted, vigilant observation to identify any breakthrough infections and careful monitoring of progression of the original infection are highly recommended. Considering a second agent (either for synergism or enhancing coverage) may be required.
